²é¿´: 2819  |  »Ø¸´: 3

sweet561

Òø³æ (СÓÐÃûÆø)

[½»Á÷] CMCÏîÄ¿ ÒÑÓÐ2È˲ÎÓë

ÏëÎʸ÷λ³æÓÑÒ»¸öÎÊÌ⣬×î½ü¹«Ë¾Ò»Ö±ÔÚ˵CMCÏîÄ¿£¬Ê²Ã´¹ØÓÚCMCÖ®ÀàµÄ£¬µ«ÎÒ²»Ì«Àí½âʲôÊÇCMC£¬ÓÖ²»ºÃÒâ˼ÔÚ¹«Ë¾ÎÊ£¬Ì«Ð¡°×ÁËËùÒÔÔÚÕâÀïÃæÏ£Íû´ó¼ÒÄܸø½âÊÍһϣ¬Ð»Ð»
»Ø¸´´ËÂ¥
ÒÑÔÄ   »Ø¸´´ËÂ¥   ¹Ø×¢TA ¸øTA·¢ÏûÏ¢ ËÍTAºì»¨ TAµÄ»ØÌû

liujinwei

½ð³æ (³õÈëÎÄ̳)

¡ï
Сľ³æ: ½ð±Ò+0.5, ¸ø¸öºì°ü£¬Ð»Ð»»ØÌû
CMC²ÄÁÏ׫дģ°å
Chemistry, Manufacturing and Controls

S DRUG SUBSTANCEÔ­ÁÏÒ©
S.1 General Information»ù±¾ÐÅÏ¢
S.1.1 NomenclatureÒ©Æ·Ãû³Æ
² International Nonproprietary NameͨÓÃÃû
² Chemical name»¯Ñ§Ãû
² Chemical Abstracts Service Registry Number CASºÅ
S.1.2 Structure½á¹¹
² structural formula (stereochemistry)½á¹¹Ê½£¨Á¢Ìå¹¹ÐÍ£©
² molecular formula·Ö×Óʽ
² molecular weight·Ö×ÓÁ¿
² amino acid sequence°±»ùËáÐòÁÐ
S.1.3 General PropertiesÀí»¯ÐÔÖÊ£¨ÁÐ±í£©
² general description (appearance, color, physical state)ÐÔ×´£¨Íâ¹Û¡¢ÑÕÉ«¡¢Îï̬£©
² melting or boiling pointsÈÛµã»ò·Ðµã
² optical rotation±ÈÐý¶È
² solubility profileÈܽâÐÔ
² solution pHÈÜÒºpH
² partition coefficients·ÖÅäϵÊý
² dissociation constants½âÀë³£Êý
² physical form (polymorph, solvate, hydrate)ÎïÖÊÐÎʽ£¨¶à¾§ÐÍÎï¡¢ÈܼÁ»¯ÎˮºÏÎ
² hygroscopicityÒýʪÐÔ
² particle size¿ÅÁ£¶È
S.2 ManufactureÉú²úÐÅÏ¢
S.2.1 ManufacturersÉú²úÉÌ
² nameÃû³Æ£»addressµØÖ·£»responsibilityÖ°Ôð£»postcodeÓʱࣻtelephone numberµç»°ºÅÂ룻fax number´«ÕæºÅÂ룻contractorÁªÏµÈË£»e-mailµç×ÓÓÊÏä
S.2.2 Description of Manufacturing Process and Process ControlsÉú²ú¹¤Òպ͹¤ÒÕ¿ØÖÆ
S.2.2.1 Flow DiagramºÏ³É·Ïßͼ/¹¤ÒÕÁ÷³Ìͼ
S.2.2.2 Description of the Manufacturing Process and Process Controls¹¤ÒÕÃèÊö
S.2.2.3 Reprocessing, Reworking, Recycling, Regeneration, and Other Operations·µ¹¤
S.2.3 Control of MaterialsÎïÁÏ¿ØÖÆ
S.2.3.1 Starting MaterialsÆðʼԭÁÏ
S.2.3.2 Reagents, Solvents, and Auxiliary MaterialsÊÔ¼Á¡¢ÈܼÁ¡¢¸¨Öú²ÄÁÏ
S.2.3.3 DiluentsÏ¡ÊͼÁ
S.2.4 Controls of Critical Steps and Intermediates¹Ø¼ü²½ÖèºÍÖмäÌåµÄ¿ØÖÆ
S.2.4.1 Critical Steps and Critical Operating Parameters¹Ø¼ü²½Öè¼°¹Ø¼ü¹¤ÒÕ²ÎÊý
S.2.4.2 Controls of IntermediatesÖмäÌå¿ØÖÆ
S.2.5 Process Validation and/or Evaluation¹¤ÒÕÑéÖ¤ºÍÆÀ¼Û
S.2.6 Manufacturing Process DevelopmentÉú²ú¹¤ÒյĿª·¢
² ºÏ³É·ÏßµÄÑ¡ÔñºÍÓÅ»¯
² ¹Ø¼ü¹¤ÒÕ²ÎÊýµÄÈ·¶¨
² ¹¤ÒÕ·Å´óÑо¿
S.3 CharacterizationÌØÐÔ¼ø¶¨
S.3.1 Elucidation of Structure and Other Characteristics½á¹¹ºÍÀí»¯ÐÔÖÊ
S.3.1.1 Elucidation of Structure½á¹¹È·Ö¤
² elemental analysisÔªËØ·ÖÎö£»MSÖÊÆ×£»NMR spectroscopyºË´ÅͼÆ×£»UV spectroscopy×ÏÍâ¹âÆ×£»IR spectroscopyºìÍâ¹âÆ×
S.3.1.2 Physicochemical CharacterizationÀí»¯ÐÔÖÊ
² X-ray diffraction (single crystal or powder)XÉäÏßÑÜÉ䣨µ¥¾§»ò·ÛÄ©£©£»particle size analysis¿ÅÁ£¶È·ÖÎö£»DSCʾ²îɨÃèÁ¿ÈÈ·¨£»FTIR¸µÁ¢Ò¶×ª»»ºìÍâÏß¹âÆ×£»TGAÈÈÖØ·ÖÎö
S.3.1.3 Biological and Other Relevant CharacteristicsÆäËûÐÔÖÊ
S.3.2 ImpuritiesÔÓÖÊ
² nameÔÓÖÊÃû³Æ£»structureÔÓÖʽṹ£»¿ØÖÆÏÞ¶È£»ÔÓÖÊÀ´Ô´£»ÊÇ·ñ¶¨ÈëÖÊÁ¿±ê×¼
S.4 Control of Drug SubstanceÔ­ÁÏÒ©µÄÖÊÁ¿¿ØÖÆ
S.4.1 SpecificationÖÊÁ¿±ê×¼£¨ÁÐ±í£©
² tests¼ì²âÏîÄ¿£ºappearanceÍâ¹Û£»identification tests¼ø±ð£»melting rangeÈ۳̣»residue on ignition³ãׯ²ÐÔü£»heavy metalsÖØ½ðÊô£»specified impuritiesÓйØÎïÖÊ£»unspecified impurities·ÇÌØ¶¨ÔÓÖÊ£»total organic impurities×ÜÔÓ£»residual solvent²ÐÁôÈܼÁ£»particle size distributionÁ£¾¶·Ö²¼£¨D10¡¢D50¡¢D90£©£»water contentË®·Ö£»¶ÔÓ³Òì¹¹Ì壻º¬Á¿²â¶¨
² release and shelf-life acceptance criteria·ÅÐбê×¼ÏÞ¶È/»õ¼ÜÆÚ±ê×¼ÏÞ¶È£ºNMT (not more than)²»¸ßÓÚ£»NLT (not less than)²»µÍÓÚ
² analytical procedure·½·¨£ºHPLC£»GC
S.4.2 Analytical Procedures·ÖÎö·½·¨£¨ÆóÒµ·½·¨£©
² º¬Á¿¼ì²â·½·¨
² ÓйØÎïÖʼì²â·½·¨
² ¶ÔÓ¦Òì¹¹Ìå¼ì²â·½·¨
² ²ÐÁôÈܼÁ¼ì²â·½·¨
S.4.3 Validation of Analytical Procedures·ÖÎö·½·¨µÄÑéÖ¤
² רÊôÐÔ£»¼ì²âÏÞ£»¶¨Á¿ÏÞ£»ÏßÐԺͷ¶Î§£»¾«Ãܶȣ»×¼È·¶È£»ÄÍÓÃÐÔ
S.4.4 Batch AnalysesÅú¼ìÑ鱨¸æ
Åú´Î1£»Åú´Î2£»Åú´Î3
S.4.5 Justification of SpecificationÖÊÁ¿±ê×¼ÖÆ¶¨ÒÀ¾Ý
S.5 Reference Standards or Materials¶ÔÕÕÆ·
S.6 Container Closure System°ü×°²ÄÁϺÍÈÝÆ÷
S.7 StabilityÎȶ¨ÐÔ
S.7.1 Stability Summary and ConclusionsÎȶ¨ÐÔ×ܽá
S.7.2 Postapproval Stability Protocol and Stability CommitmentÉÏÊкóÎȶ¨ÐÔ·½°¸ºÍ³Ðŵ
S.7.3 Stability DataÎȶ¨ÐÔÊý¾Ý

P DRUG PRODUCTÖÆ¼Á
P.1 Description and Composition of the Drug Product¼ÁÐͼ°²úÆ·×é³É
² component³É·Ö£»amountÓÃÁ¿£»overage¹ýÁ¿£»function×÷Óã»quality standardÖÊÁ¿±ê×¼
P.2 Pharmaceutical Development²úÆ·¿ª·¢
P.2.1 Components of the Drug Product´¦·½×é³É
P.2.1.1 Drug SubstanceÔ­ÁÏÒ©
² the compatibility of the drug substance with the excipientsÔ­ÁÏÒ©Ó븨ÁϵÄÏàÈÝÐÔ
² key physicochemical characteristicsÖØÒªÀí»¯ÐÔÖÊ
P.2.1.2 Excipients¸¨ÁÏ
² the choice of excipients¸¨ÁÏÖÖÀàµÄÑ¡Ôñ
² concentration of excipients¸¨ÁϵÄÓÃÁ¿
P.2.2 Drug ProductÖÆ¼ÁÑо¿
P.2.2.1 Formulation Development´¦·½¿ª·¢¹ý³Ì
P.2.2.2 Overages¹ýÁ¿
P.2.2.3 Physicochemical and Biological PropertiesÀí»¯ÌØÐÔºÍÉúÎïÑ§ÌØÐÔ
P.2.3 Manufacturing Process DevelopmentÉú²ú¹¤ÒյĿª·¢
P.2.4 Container Closure System°ü×°²ÄÁϺÍÈÝÆ÷
² the suitability of the container closure system°ü×°²ÄÁϺÍÈÝÆ÷µÄºÏÊÊÐÔ
P.2.5 Microbiological Attributes΢ÉúÎïÐÔÖÊ
P.2.6 CompatibilityÏàÈÝÐÔ
² the compatibility of the drug product with reconstitution diluents or dosage devices
P.3 ManufactureÉú²úÐÅÏ¢
P.3.1 ManufacturersÉú²úÉÌ
² nameÃû³Æ£»addressµØÖ·£»responsibilityÖ°Ôð£»contractorÁªÏµÈË
P.3.2 Batch FormulaÅú´¦·½
² component³É·Ö£»amountÓÃÁ¿£»overage¹ýÁ¿£»function×÷Óã»quality standardÖÊÁ¿±ê×¼
P.3.3 Description of Manufacturing Process and Process ControlsÉú²ú¹¤Òպ͹¤ÒÕ¿ØÖÆ
P.3.2.1 Flow Diagram¹¤ÒÕÁ÷³Ìͼ
P.3.2.2 Description of the Manufacturing Process and Process Controls¹¤ÒÕÃèÊö
P.3.4 Controls of Critical Steps and Intermediates¹Ø¼ü²½ÖèºÍÖмäÌåµÄ¿ØÖÆ
P.3.5 Process Validation and/or Evaluation¹¤ÒÕÑéÖ¤ºÍÆÀ¼Û
² ¹¤ÒÕÑéÖ¤·½°¸
² ¹¤ÒÕÑéÖ¤±¨¸æ
P.4 Control of Excipients¸¨ÁϵĿØÖÆ
P.4.1 SpecificationsÖÊÁ¿±ê×¼
P.4.2 Analytical Procedures·ÖÎö·½·¨
P.4.3 Validation of Analytical Procedures·ÖÎö·½·¨µÄÑéÖ¤
P.4.4 Justification of SpecificationsÖÊÁ¿±ê×¼ÖÆ¶¨ÒÀ¾Ý
P.4.5 Excipients of Human or Animal OriginÈËÔ´»ò¶¯ÎïÔ´¸¨ÁÏ
P.4.6 Novel Excipientsи¨ÁÏ
P. 5 Control of Drug ProductÖÆ¼ÁµÄÖÊÁ¿¿ØÖÆ
P.5.1 SpecificationsÖÊÁ¿±ê×¼
² tests¼ì²éÏîÄ¿£ºdescriptionÐÔ×´£»identification test¼ø±ð£»core weightÖØÁ¿²îÒ죻dissolutionÈܳö¶È£»water contentË®·Ö£»specified degradation productsÓйØÎïÖÊ£»unspecified degradation product·ÇÌØ¶¨ÔÓÖÊ£»total degradation products×ÜÔÓ£»residual solvent²ÐÁôÈܼÁ£»Î¢ÉúÎïÏÞ¶È£»º¬Á¿²â¶¨
² release and shelf-life acceptance criteria·ÅÐбê×¼ÏÞ¶È/»õ¼ÜÆÚ±ê×¼ÏÞ¶È£ºNMT (not more than)²»¸ßÓÚ£»NLT (not less than)²»µÍÓÚ
² analytical procedure·½·¨£ºHPLC£»GC
P.5.2 Analytical Procedures·ÖÎö·½·¨
² º¬Á¿²â¶¨·½·¨
² ÓйØÎïÖʼì²â·½·¨
² Èܳö¶È²â¶¨·½·¨
² ÖØÁ¿²îÒì²â¶¨·½·¨
² ΢ÉúÎïÏ޶ȼì²é·½·¨
P.5.3 Validation of Analytical Procedures·ÖÎö·½·¨µÄÑéÖ¤
² ²¨³¤Ñ¡Ôñ£»×¨ÊôÐÔ£»ÏµÍ³ÊÊÓÃÐÔ£»¼ì²âÏÞ£»ÈÜÒºÎȶ¨ÐÔ£»ÄÍÓÃÐÔ£»ÏßÐÔÓ뷶Χ£»¶¨Á¿ÏÞ£»»ØÊÕÂÊ£»¾«Ãܶȣ»×¼È·¶È
P.5.4 Batch AnalysesÅú¼ìÑ鱨¸æ
Åú´Î1£»Åú´Î2£»Åú´Î3
P.5.5 Characterization of ImpuritiesÔÓÖÊ·ÖÎö
² nameÔÓÖÊÃû³Æ£»structureÔÓÖʽṹ£»¿ØÖÆÏÞ¶È£»ÔÓÖÊÀ´Ô´£»ÊÇ·ñ¶¨ÈëÖÊÁ¿±ê×¼
P.5.6 Justification of SpecificationsÖÊÁ¿±ê×¼ÖÆ¶¨ÒÀ¾Ý
P.6 Reference Standards or Materials¶ÔÕÕÆ·
P.7 Container Closure System°ü×°²ÄÁϺÍÈÝÆ÷
P.8 StabilityÎȶ¨ÐÔ
P.8.1 Stability Summary and ConclusionsÎȶ¨ÐÔ×ܽá
P.8.2 Postapproval Stability Protocol and Stability CommitmentÉÏÊкóÎȶ¨ÐÔ·½°¸ºÍ³Ðŵ
² °ü×°²ÄÁÏ
² Öü²ØÌõ¼þ
² ÓÐЧÆÚ
P.8.3 Stability DataÎȶ¨ÐÔÊý¾Ý
² Ó°ÏìÒòËØÊÔÑ飨¸ßΡ¢¸ßʪ¡¢¹âÕÕ£©
² ¼ÓËÙÊÔÑé
² ³¤ÆÚÊÔÑé
2Â¥2017-11-21 17:01:33
ÒÑÔÄ   »Ø¸´´ËÂ¥   ¹Ø×¢TA ¸øTA·¢ÏûÏ¢ ËÍTAºì»¨ TAµÄ»ØÌû

sweet561

Òø³æ (СÓÐÃûÆø)

ÒýÓûØÌû:
2Â¥: Originally posted by liujinwei at 2017-11-21 17:01:33
CMC²ÄÁÏ׫дģ°å
Chemistry, Manufacturing and Controls

S DRUG SUBSTANCEÔ­ÁÏÒ©
S.1 General Information»ù±¾ÐÅÏ¢
S.1.1 NomenclatureÒ©Æ·Ãû³Æ
² International Nonproprietary NameͨÓÃÃû
...

Ì«¸ÐлÁË
3Â¥2017-11-22 10:26:48
ÒÑÔÄ   »Ø¸´´ËÂ¥   ¹Ø×¢TA ¸øTA·¢ÏûÏ¢ ËÍTAºì»¨ TAµÄ»ØÌû

ËÎÔ¶ÌÎ

Ìú¸Ëľ³æ (ÖøÃûдÊÖ)

ÌÎ:tuzi24:

ҩѧ²¿·Ö
4Â¥2017-11-23 16:07:04
ÒÑÔÄ   »Ø¸´´ËÂ¥   ¹Ø×¢TA ¸øTA·¢ÏûÏ¢ ËÍTAºì»¨ TAµÄ»ØÌû
Ïà¹Ø°æ¿éÌø×ª ÎÒÒª¶©ÔÄÂ¥Ö÷ sweet561 µÄÖ÷Ìâ¸üÐÂ
×î¾ßÈËÆøÈÈÌûÍÆ¼ö [²é¿´È«²¿] ×÷Õß »Ø/¿´ ×îºó·¢±í
[¿¼ÑÐ] ²ÄÁϵ÷¼Á +5 Æ¥¿Ëi 2026-03-23 5/250 2026-03-24 08:50 by dick_runner
[¿¼ÑÐ] 327Çóµ÷¼Á +5 prayer13 2026-03-23 5/250 2026-03-23 22:11 by ÐÇ¿ÕÐÇÔÂ
[¿¼ÑÐ] Ò»Ö¾Ô¸211 ³õÊÔ270·Ö Çóµ÷¼Á +4 ¹ÈÓêÉϰ¶ 2026-03-23 5/250 2026-03-23 21:18 by ²»»ó¿ÉÀÖ
[¿¼ÑÐ] 265Çóµ÷¼Á +10 ÁºÁºÐ£Ð£ 2026-03-17 10/500 2026-03-23 21:17 by Ò»ÇÐOK
[¿¼ÑÐ] 291 Çóµ÷¼Á +4 »¯¹¤2026½ì±ÏÒµÉ 2026-03-21 5/250 2026-03-23 16:46 by »¯¹¤2026½ì±ÏÒµÉ
[¿¼ÑÐ] Çóµ÷¼Á²ÄÁÏѧ˶080500£¬×Ü·Ö289·Ö 5+3 @taotao 2026-03-19 21/1050 2026-03-23 10:17 by ¹Úc¸ç
[¿¼ÑÐ] Çóµ÷¼ÁÒ»Ö¾Ô¸º£´ó£¬0703»¯Ñ§Ñ§Ë¶304·Ö£¬Óдó´´ÏîÄ¿£¬Ëļ¶Òѹý +6 ÐÒÔËÁ¨Á¨ 2026-03-22 10/500 2026-03-22 20:10 by edmund7
[¿¼ÑÐ] 275Çóµ÷¼Á +6 shansx 2026-03-22 8/400 2026-03-22 15:27 by barlinike
[¿¼ÑÐ] ÉúÎïѧµ÷¼Á +5 Surekei 2026-03-21 5/250 2026-03-22 14:39 by tcx007
[¿¼ÑÐ] 318Çóµ÷¼Á +4 plumÀî×Ó 2026-03-21 7/350 2026-03-22 14:17 by ColorlessPI
[¿¼ÑÐ] ²ÄÁÏÓ뻯¹¤£¨0856£©304ÇóBÇøµ÷¼Á +3 Çñgl 2026-03-20 7/350 2026-03-21 19:05 by 15709483992
[¿¼ÑÐ] 297Çóµ÷¼Á +11 Ï·¾«µ¤µ¤µ¤ 2026-03-17 12/600 2026-03-21 17:47 by ColorlessPI
[¿¼ÑÐ] 336Çóµ÷¼Á +5 rmc8866 2026-03-21 5/250 2026-03-21 17:24 by ѧԱ8dgXkO
[¿¼ÑÐ] 268Çóµ÷¼Á +9 ¼òµ¥µã0 2026-03-17 9/450 2026-03-21 15:37 by lature00
[¿¼ÑÐ] 265Çóµ÷¼Á +3 Jack?k?y 2026-03-17 3/150 2026-03-21 03:17 by JourneyLucky
[¿¼ÑÐ] 083200ѧ˶321·ÖÒ»Ö¾Ô¸ôßÄÏ´óѧÇóµ÷¼Á +3 innocenceF 2026-03-17 3/150 2026-03-21 02:35 by JourneyLucky
[¿¼ÑÐ] ²ÄÁÏѧ˶297ÒѹýËÄÁù¼¶Çóµ÷¼ÁÍÆ¼ö +11 adaie 2026-03-19 11/550 2026-03-20 21:30 by laoshidan
[¿¼ÑÐ] 086500 325 Çóµ÷¼Á +3 Áì´øÐ¡ÐÜ 2026-03-19 3/150 2026-03-20 18:38 by ¾¡Ë´Ò¢1
[¿¼ÑÐ] 288Çóµ÷¼Á£¬Ò»Ö¾Ô¸»ªÄÏÀí¹¤´óѧ071005 +5 ioodiiij 2026-03-17 5/250 2026-03-19 18:22 by zcl123
[¿¼ÑÐ] 0703»¯Ñ§µ÷¼Á +4 18889395102 2026-03-18 4/200 2026-03-19 16:13 by 30660438
ÐÅÏ¢Ìáʾ
ÇëÌî´¦ÀíÒâ¼û